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The heart failure (HF) is one of the main
health problems of all economically developed
countries. According to the recent survey data,
its spreading among the population increases;
for this reason there is a necessity for develop<
ment in essence new, accessible and effective
methods of HF correction. New cell technolo<
gies in cardiology are integrated by the term
«cellular cardiomyoplasty» similar to differ<
ent techniques of «cardiomyoplasty» which are
intended to change the processes of remodeling
of the myocardium and to influence its regen<
eration. So that all of them lead to the improve<
ment of functions of a cardiac muscle [1].
The most often cause of HF is acute myo<
cardium infarction. The miscellaneous patho<
logical processes in the myocardium are accom<
panied by its complex adaptive — compensator
rearrangement — «remodeling». Remodeling
of the myocardium is a process of serious adap<
tive structurally functional changes of a car<
diac muscle as a result of its damage. The
processes of remodeling take part both in the
zone of damage, and in able<bodied myocardi<
um. The zone of infarct is step<by<step expand<
ed and punched, and the unimpaired sites are
hypertrophied and later are dilated, adapting
to new conditions of functioning [2, 3].
The two<decade<old field of tissue engi<
neering relies on the body’s own repair mecha<
nisms. It was considered that the damages of a
cardiac muscle are irreversible and they result
in remodeling under the scenario described
above and are often finished by development of a
heart failure within several months or years [4].
J. Kajstura  et al. [5] have demonstrated that the
mitosises of cardiomyocytes are possible, but
they are very rare terminated by cytokinesis and
are located, mainly, in periinfarct area and, as a
consequent, can not substitute a defect which
appeared after the damage of the myocardium. It
is determined that a mitotic index of cardiomy<
ocytes in pathological heart (cardiomyopathy) is
approximately 10 times higher than in normal
myocardium, that is, the proliferation of cardiac
cells plays the relevant role in compensator
processes of the myocardium.
Although a population of self<renewing
stem cells in the hearts of mammals (human,
mouse, dog) has been discovered, it is not
enough to restore the cardiac tissue after mas<
sive myocardial infarction which leads quickly
to cardiomyocytes death and the loss of tissue.
As a result, replacement of defect of a cardiac
muscle occurs, mainly, due to a proliferation
of stromal cells (fibroblasts) [6].
The development of biotechnology, molec<
ular and cell biology has made a cell not only
the main object of influences, but also a tool
for treatment of many diseases. Cell trans<
plantation has a number of relevant advan<
tages in comparison with the replacement of
the whole organ. One of these advantages is
that the cell therapy permits to obtain cell
populations saved of an impurity of extraanti<
40
The review article is devoted to cellular cardiomyoplasty as a novel technology of treatment of cardiac insuffi<
ciency. The experiments on animals and the first clinical trials have shown the possibility to improve the contractile
function of diseased heart after transplantation of different types of donor cells: cardiomyocytes, bone marrow
enriched by hematopoietic stem cells and mesenchymal stem cells. The problems of cellular cardiomyoplasty are dis<
cussed.
UDK 612.173:576.343
CELL THERAPY OF HEART PATHOLOGIES
L. L. LUKASH
Institute of Molecular Biology and Genetics 
of National Academy of Sciences of Ukraine, Kyiv
E$mail: lukash@imbg.org.ua
Key words: Cellular cardiomyoplasty, stem cell, cardiomyocyte, differentiation, tissue engineering in
vitro, experimental models of myocardial infarction in vivo, autologeous, allogenic and xenogenic transplantation.
Огляди 
41
genic donor cells, which first of all participate
in the process of immune rejection by using of
cultural methods. Another advantage is that
in comparison with organ transplantation,
such operations are more accessible and cheap<
er for the patients. There is a capability to
realize repeated cell transplantations. 
Nowadays polipotent stem cells become
a new source of cellular material for transplan<
tation because they are capable to differentiate
into different types of cells under the influence
of microenvironment and specific growth fac<
tors ensuring information conditioning [7].
For the first time in 2001 [8], the results
which testified a capability of human embry<
onic stem cells to differentiate into cardiomy<
ocytes were published. In 2003 it was reported
[9] that cardiomyocytes might be derived from
embryonic stem cells, embryonic germ cells,
cord blood cells and peripheral blood under the
influence of microenvironment and specific
growth factors in vitro.  
The strategy of cardiomyogenic differenti<
ation of mesenchymal stem cells using the
composition of growth factors and the media
conditioned by primary cardiomyocytes has
been developed in the Institute of Molecular
Biology and Genetics of NAS of Ukraine [10].
We obtained adult mesenchymal stem cell
lines (CB<1, 4BL and SK<1) originated from
cord blood, peripheral blood and skin of adult
donors by cultural methods and cultivated the
cells in vitro during 40–100 passages. Then the
human mesenchyme<like cells have been
passed in regular DMEM medium with 10 % of
fetal bovine serum or in the same medium with
addition of special growth factors which
induce cardiomyogenic differentiation [11,
12]. The parental and differentiated cells have
been characterized by cytogenetical method
and immunophenotyping (Fig.). After long
time cultivation in differentiation medium
the studied cell populations contained more
than 90% of myocytes which carried anti<A<
smooth muscle marker. Practically this
approach allows us to obtain and to keep cry<
opreserved unlimited amount of cells for
research in different fields. We think that one
of the most important and attractive field for
application of the human cell lines obtained by
us is the development of technology for cellu<
lar cardiomyoplasty which could be realized
within hours after myocardial infarction.     
A number of research works demonstrates
a perspective development of cellular car
diomyoplasty [13]. T. Reffelmann et al. [13]
have shown in 2003 that the transplantation of
neonatal cardiomyocytes induces angiogenesis
The morphology of differentiated and expanded
in vitro cardiomyocytes [10,11]:
1 — Embryoid body with contractile area,
formed by human embryonic germ cells;
2 — Growing individual cells, isolated from con<
tractile area, after staining;
3 — Intercellular contacts between growing cells;
4 — Monolayer of stained cardiomyocytes;
5 — Scheme images of early differentiated car<
diomyocytes;
6 — Stained chromosomes of individual cardio<
myocyte
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in zones of acclimation of cellular transplant<
ed body. J. Leor et al. [14] have observed that
cardiomyocytes grown in polymer carriers
reshape a teleorgаnic tissue and stimulate neo<
vascularizations. T. McDevitt et al. [15] have
shown that elastomeric polyurethane film,
which is biodegraded material, can serve as
the optimal carrier to support the stability of
3D<culture of cardiomyocytes, that is the new
technology of transplantation of organized
heart tissue constructions with the purpose of
myocardium reparation.
Morphological, physiological, immunophe<
notypical and molecular<genetic features of
populations of cardiomyocytes, which are culti<
vated in vitro, have been studied with the pur<
pose of their practical usage [16, 17]. It is
known that postnatal cardiomyocytes have
very poor growth potential in vitro and in vivo.
At the same time, fetal cells have more poten<
tial to grow in culture and in an organism of the
recipient comparing with postnatal ones. Thus,
they excrete biologically active compounds —
inducers of cardiomyocytes regeneration and
myocardium remodeling, that is an informa<
tion signal for implementation of definite bio<
chemical process and a component of biochemi<
cal reaction of this process in an ambient tissue. 
J. Wang et al. [18] offered and confirmed
experimentally the hypothesis that microenvi<
ronment of the myocardium creates certain con<
ditions and signals for cardiomyogenic differen<
tiation. In their research muscle stem cells of rat
after cultivation and removing the majority of
hematopoietic stem cells, were grafted into
myocardium and were differentiated into car<
diomyocytes, created slot<hole contacts. B.
Leobon et al. [19] found that grafted myoblasts
are differentiated into specific myofibriles with
completely independent contractile activity in
relation to adjacent cardiomyocytes.  
S. Makino et al. [20] have obtained car<
diomyogenic cell line from murine stromal cells
of the bone marrow. After treatment with 5<aza<
cytidine in vitro, the processes of cardiomyo<
genic differentiation were induced. The
obtained cells expressed a lot of genes specific
for cardiomyocytes, had phenotype of fetal car<
diomyocytes of heart ventricle. Cardiomyocytes
differentiated by this way contracted sponta<
neously, were connected among themselves by
plug<in disks, formed myotubes, had a metas<
tructure, characterictic for cardiomyocytes.
The myotubes generated action potential, which
resembled those in ventricular cells.
L. Klug et al. [21] modified pluripotent
embryonic stem cells genetically with the pur<
pose that cardiomyogenic way of their differ<
entiation would dominate in cellular popula<
tion. They generated a line of stem cells,
which carried a gene for heavy chain of
myosin. Immunohistological and ultrastruc<
tural analysis showed, that cardiomyocytes
obtained by this way were highly differentiat<
ed (99 % of cells contained myosin, myofib<
riles, the plug<in disks) and formed grafts in
the hearts of adult mice during 7 weeks after
implantation. It has been observed the appear<
ance of all components of plug<in disks
between recipient and donor cardiomyocytes
in the myocardium of dogs, which had inheri<
table muscle dystrophia, in 10 weeks after
transplantation of fetal cardiomyocytes [22].
R. Li et al. [23] were engaged in transplanta<
tion of fetal cardiomyocytes and cardiomyocytes
of newborn rats. The authors of this work
observed that the cardiomyocytes grown up in
vitro formed a heart<like tissue both the struc<
ture as well as the functions. Cardiomyocytes
contained the organized sarcomeres and were
joined by intercellular contacts, which actuated
desmosomes and fascia adherences. Cardiomyo<
cytes were regularly, spontaneously and synchro<
nously contracted in vitro. The comparative
analysis had shown that the transplantation was
more successful when introducing fetal cells
rather than the neonatal cell material of 5<day’s
rats. In the first case up to 92 % of cells survived,
in the other case it was only 50 % of survival. The
cells isolated from young 22<day’s and adult 32<
day’s animals did not survive in adult heart after
a transplantation. The same authors have shown
that the transplantation of autologous cardiomy<
ocytes from mature animals into cryodamaged
myocardium permitted only to persist them in
the tissues during 5 weeks (duration of research).
However, grafted cells modified the process of
the myocardium remodeling: rendered assistance
to avoid its dilatation and expansion of cicatrix,
to preserve the depth of its wall. 
J. Leor et al. [24] carried out a transplan<
tation of allogenic fetal heart tissue to rats at
different terms after a myocardial infarction
and observed that the cells persisted up to 65
days, saved fetal phenotype and did not differ<
entiated in mature cardiomyocytes. 
At the same time, applications of allogenic
fetal cardiomyocytes in clinical practice is lim<
ited by ethical standards and by the necessity
to use the immunosupression as well, which by
itself does not guarantee long<term existence
of grafted material and reduces efficiency of
transplantation. Therefore, for clinical usage
advantage returns to an autologous material,
such as the populations of mesenchymal stem
cells of the bone marrow, in which it is possi<
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ble to induce cardiomyogenic differentiation.
It has been shown that the injection of bone
marrow cells into infarcted myocardium in
mice resulted in some improvement in cardiac
function and a decrease of infarcted zone [25<
28]. However, in prior studies the investiga<
tors have used hemopoietic stem cells rather
than mesenchymal cell precursors which are
much less immunogenic [2,3].
An approach is developed for direct intra<
venous injection of allogenic bone marrow<
derived mesenchymal stem cells for improve<
ment of left ventricular function in the
porcine model of myocardial infarction [29].
Direct intramyocardial injection of mesenchy<
mal stem cells results in successful intramy<
ocardial engraftment and differentiation into
cardiomyocytes and endothelial cells and pre<
serves left ventricular function after myocar<
dial infarction in pigs [30].
S. Fukuhara et al. [31] have demonstrated,
that the direct intercellular interaction with
cardiomyocytes plays a key role in differentia<
tion of stromal cells of the bone marrow into
cardiomyocytes. The culture obtained is suit<
able for recovery of cardiomicroenvironment
in vitro with the purpose of investigation of
cell transplantation in cardiology. 
Clinical trials of the methods of cell thera<
py are under way now. They have been started
with using mostly autologous mixed cell popu<
lations from the bone marrow or cell popula<
tions enriched in hemopoietic CD34+ stem cells
or mesenchymal stem cells (only in some cases).
The results of clinical trials vary in different
medical centers [32]. In general, clinicians
pointed out that all the studies were done safe
and that some patients fared better after the
trials. At the same time, they show a modest
improvement (6,0–8,5 %) in heart function. 
One of the main problems of cellular car<
diomyoplasty is poor efficiency. Difficulties in
the implementation of this progressive method
can be connected with the limited cell source, an
absence of designed criteria for estimation of
quality and quantity of cell material prepared
for transplantation. Another problem is that
the patients after acute myocardium infarction
need help immediately. In such a situation it is
better to keep a cellular bank of standardized
allogenic cells prepared for cell therapy.
It is considered now that probably the opti<
mal cell type for cardiomyoplasty is cardiomy<
ocyte progenitor cell. Cardiac stem cells or
progenitors of cardiomyocytes with marker
isl<1+ have been identified in the hearts of dif<
ferent mammals. It has been shown that these
cells participate in the regeneration of dam<
aged myocardium [33–37].  So, in principal, it
is possible to get biopsy from cardiac tissue of
a patient and to isolate isl<1+ cells for expan<
sion in vitro. Autologous cells should be har<
vested, separated and then grown up in cul<
ture before injection. But it is obvious that the
procedure of their preparing for practical
application will take a long time.  
Another possibility is to use allogenic mes<
enchymal stem cells differentiated into prog<
enitors of cardiomyocytes in vitro. It is known
that the prominent characteristic feature of
terminally differentiated cardiomyocytes is
their capacity to spontaneous automatic con<
tractions. The experiments on obtaining the
cardiomyocytes in culture and registration of
their images conducted at the Institute of
Molecular Biology and Genetics and Institute
of Cybernetics of NAS of Ukraine, Kiev, have
shown that the cells, grown up by conventional
technique, have slower rhythm of contractions
(from 20 up to 60 beats per minute) compared
to a normal rhythm of human heart [11].
According to the data of other authors car<
diomyocytes, which are cultured in vitro, some<
times reveal higher rhythm of spontaneous con<
tractions, than the normal heart [7]. The
mechanisms of rhythmogenesis are intensively
investigated in experimental models [38].
There is basis to consider that this is the
divergence in rhythms which creates informa<
tional noncompatibility of tissues. The diver<
gence in rhythms, apparently, results in
incompatibility of physiological processes,
which descend in recipient organ particularly,
and in an organism as a whole. Probably, with
realization of operations on cell transplanta<
tion in the case, for example, of myocardial
infarction, one of the causes of unsatisfactory
functional outcomes can be an arrhythmia or
noncompatibility of rhythms of contractions
of transplanted biological tissue and a recipi<
ent organ. The authors [19] have observed that
the grafted myoblasts are differentiated in
specific myofibriles with completely indepen<
dent contractile activity in relation to adjacent
cardiomyocytes. So, another problem which
should be resolved in future is biological
sychronization of the cardiomyocytes of
a patient and injected cells. 
Nowadays cell transplantation is esteemed
by the majority of the explorers as the alterna<
tive to organ transplantation. Apparently, it
will be applied in clinical practice for improve<
ment of the forecast in patients with a heart fail<
ure of different genesis (myocardial infarction,
wound of heart, dilatation cardiomyopathy
etc.). From the established facts, it is possible to
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draw a conclusion that selection of stem cell
type (fetal or postnatal), direction and condi<
tions of differentiation, culture conditions and
information compatibility of biological objects
influence the success of transplantation.
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Оглядова стаття присвячена клітинній кар<
діоміопластиці як новій технології лікування
серцевої недостатності. Експерименти на тва<
ринах і перші клінічні випробування показали
можливість поліпшення скорочувальної функ<
ції ураженого міокарда після трансплантації
різних типів клітин: кардіоміоцитів, кістково<
го мозку, збагаченого гемопоетичними стовбу<
ровими клітинами, а також мезенхімальних
стовбурових клітин. Обговорюються проблеми
клітинної кардіоміопластики.
Ключові слова: клітинна кардіоміопласти<
ка, стовбурові клітини, кардіоміоцити, тканин<
на інженерія в культурі, експериментальні мо<
делі інфаркту міокарда in vivo, аутологічна,
алогенна, ксеногенна трансплантація.
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Обзорная статья посвящена клеточной кар<
диомиопластике как новой технологии лечения
сердечной недостаточности. Эксперименты на
животных и первые клинические испытания
новой технологии показали возможность улуч<
шения сократительной функции пораженного
миокарда после трансплантации различных ти<
пов клеток: кардиомиоцитов, костного мозга,
обогащенного гемопоэтическими стволовыми
клетками, а также мезенхимальных стволовых
клеток. Обсуждаются проблемы клеточной
кардиомиопластики.
Ключевые слова: клеточная кардиомио<
пластика, стволовые клетки, кардиомиоциты,
тканевая инженерия в культуре, эксперимен<
тальные модели инфаркта миокарда in vivo,
аутологичная, аллогенная, ксеногенная тран<
сплантация.
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